+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations

Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations

Clinical Pharmacokinetics 43(6): 361-394

Depressive and anxiety disorders appear during the transplant process due to psychological stressors, medications and physiological disturbances. Treatment is necessary to prevent impact on patient compliance, morbidity and mortality. Psychotropic medications provide an effective option, although most are only available as oral formulations. Because of this, they are more susceptible to alterations in pharmacokinetic behaviour arising from organ dysfunction in the pretransplant period. Kinetics are also an issue when considering potential drug-drug interactions before and after transplantation. Prior to transplant, organ dysfunction can change the pharmacokinetic behaviour of some psychotropic agents, requiring adjustment of dosage and schedules. Thoracic or abdominal organ failure may reduce drug absorption through disturbances in intestinal motility, perfusion and function. Cirrhotic patients experience increased drug bioavailability due to portosystemic shunting, and thus dosage is adjusted downward. In contrast, dosage needs to be raised when peripheral oedema expands the drug distribution volume for hydrophilic and protein-bound agents. Drug clearance for most psychotropic medications is dependent upon hepatic metabolism, which is often disrupted by endstage organ disease. Selection of drugs or their dosage may need to be adjusted to lower the risk of drug accumulation. Further adjustments in dosage may be called for when renal failure accompanies thoracic or abdominal organ failure, resulting in further impairment of clearance. Studies regarding the treatment of anxiety and depressive disorders in the medically ill are limited in number, but recommendations are possible by review of clinical and pharmacokinetic data. Selective serotonin reuptake inhibitors are well tolerated and efficacious for depression, panic disorder and post-traumatic stress disorder. Adjustments in dosage are required when renal or hepatic impairment is present. Among them, citalopram and escitalopram appear to have the least risk of drug-drug interactions. Paroxetine has demonstrated evidence supporting its use with generalised anxiety disorder. Venlafaxine is an alternative option, beneficial in depression, post-traumatic stress and generalised anxiety disorders. Nefazodone may also be considered, but there is some risk of hepatotoxicity and interactions with immunosuppressant drugs. Mirtazapine still needs to be studied further in anxiety disorders, but can be helpful for depression accompanied by anorexia and insomnia. Bupropion is effective in the treatment of depression, but data are sparse about its use in anxiety disorders. Psychostimulants are a unique approach if rapid onset of antidepressant action is desired. Acute or short-term anxiolysis is obtained with benzodiazepines, and selection of particular agents entails consideration of distribution rate, half-life and metabolic route.

(PDF same-day service: $19.90)

Accession: 035980979

Download citation: RISBibTeXText

PMID: 15086275

DOI: 10.2165/00003088-200443060-00002

Related references

Course of symptom change during anxiety treatment: Reductions in anxiety and depression in patients completing the Coordinated Anxiety Learning and Management program. Psychiatry Research 229(1-2): 133-142, 2016

Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the hospital, Anxiety and Depression Scale (HADS). Bmc Psychiatry 12: 6-6, 2012

Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clinical Pharmacokinetics 41(2): 115-135, 2002

Anxiety and depression in cancer patients: Relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. Journal of Psychosomatic Research 49(1): 27-34, July, 2000

Symptoms of anxiety and depression in liver-transplant patients. Actas Espanolas de Psiquiatria 32(4): 222-226, 2004

Anxiety and depression in mothers of children undergoing bone marrow transplant: symptom prevalence and use of the Beck depression and Beck anxiety inventories as screening instruments. Journal of Consulting and Clinical Psychology 69(6): 1037-1047, 2002

Practical considerations in the pharmacologic treatment of depression and anxiety in the elderly. Journal of Clinical Psychiatry 51 Suppl: 40-43, 1990

Pharmacologic considerations in the treatment of anxiety and depression in medical practice. Medical Clinics of North America 55(2): 485-494, 1971

Screening for anxiety and depression in dialysis patients: comparison of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory. Journal of Psychosomatic Research 73(2): 139-144, 2012

Discriminant validity of the Hospital Anxiety and Depression Scale, Beck Depression Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of depression and anxiety in patients with chronic obstructive pulmonary disease. Chronic Respiratory Disease 13(3): 220-228, 2016

Anxiety and depression: a comparison between renal transplant recipients and hemodialysis patients. Transplantation Proceedings 39(4): 1082-1084, 2007

Assessing onset of treatment benefit in depression and anxiety: conceptual considerations. Journal of Clinical Psychiatry 70(8): 1138-1145, 2009

Caregiver Burden, Anxiety, Depression, and Sleep Quality Differences in Caregivers of Hemodialysis Patients Compared With Renal Transplant Patients. Transplantation Proceedings 47(5): 1388-1391, 2016

The pharmacologic treatment of anxiety and depression in African Americans. Considerations for the general practitioner. Archives of Family Medicine 6(4): 371-375, 1997